Want to see LENZ full AI Analyst Report?
LENZ Stock Chart & Stats
$5.48
$0.43(8.51%)
At close: 4:00 PM EDT
$5.48
$0.43(8.51%)
Day’s Range― - ―
52-Week Range$4.68 - $50.40
Previous CloseN/A
Volume1.43M
Average Volume (3M)987.64K
Market Cap
$163.36M
Enterprise Value-$41.23
Total Cash (Recent Filing)$220.00M
Total Debt (Recent Filing)$122.00K
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 11, 2026EPS Estimate
-0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.09
Shares Outstanding31,354,395
10 Day Avg. Volume1,204,394
30 Day Avg. Volume987,643
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)1.62
Price to Sales (P/S)24.15
P/FCF Ratio-6.59
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$24.40Price Target Upside345.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.49
Revenue Forecast (FY)$18.98M
Bulls Say, Bears Say
Bulls Say
High Product Gross Margins And Growing RevenueSustained ~90% direct product gross margins indicate durable unit economics: as volumes scale, revenue converts to high incremental profit. Combined with rising TTM revenue, strong product-level margins create a clear path to operating leverage and eventual profitability if commercialization execution continues.
Conservative Balance Sheet With Minimal DebtExtremely low leverage and sizable equity/assets reduce refinancing and bankruptcy risk, giving management runway to fund commercialization and regulatory activities without reliance on costly debt. This financial flexibility supports sustained investment in key growth initiatives.
Strong Early Patient Persistence And E‑pharmacy ChannelHigh repeat purchase rates and dominant e‑pharmacy share signal durable customer retention and predictable lifetime demand. The direct channel supplies patient‑level data for cohort analysis and targeted marketing, enabling scalable, data‑driven commercialization and higher long‑term revenue visibility versus one‑time scripts.
Bears Say
Significant Cash Burn And Negative Free Cash FlowPersistent negative operating and free cash flows require ongoing external financing, which can dilute shareholders and limit strategic flexibility. Continued high cash consumption constrains the company’s ability to sustain multi‑channel commercialization or fund regulatory activities absent meaningful revenue acceleration.
Operating Losses Far Exceed Early Product RevenuesA large gap between nascent product sales and a hefty operating cost base means profitability depends on rapid, sustained scale. If customer acquisition costs remain high or retention weakens outside e‑pharmacy, the firm may fail to achieve the necessary margin expansion before capital constraints bite.
Limited Retail Pickup And Conversion Friction In TelehealthWeak retail presence and screening attrition in telehealth create structural barriers to reaching broad patient populations. Reliance on e‑pharmacy and consumer‑initiated scripts may cap market penetration; durable growth requires resolving retail conversion and streamlining telehealth funnels to scale beyond early adopter cohorts.
LENZ Therapeutics News
LENZ FAQ
What was Lenz Therapeutics, Inc.’s price range in the past 12 months?
Lenz Therapeutics, Inc. lowest stock price was $4.68 and its highest was $50.40 in the past 12 months.
What is Lenz Therapeutics, Inc.’s market cap?
Lenz Therapeutics, Inc.’s market cap is $163.36M.
When is Lenz Therapeutics, Inc.’s upcoming earnings report date?
Lenz Therapeutics, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 90 days.
How were Lenz Therapeutics, Inc.’s earnings last quarter?
Lenz Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$1.02 earnings per share for the quarter, beating the consensus estimate of -$1.05 by $0.03.
Is Lenz Therapeutics, Inc. overvalued?
According to Wall Street analysts Lenz Therapeutics, Inc.’s price is currently Undervalued.
Does Lenz Therapeutics, Inc. pay dividends?
Lenz Therapeutics, Inc. pays a Weekly dividend of $7.21 which represents an annual dividend yield of N/A. See more information on Lenz Therapeutics, Inc. dividends here
What is Lenz Therapeutics, Inc.’s EPS estimate?
Lenz Therapeutics, Inc.’s EPS estimate is -0.93.
How many shares outstanding does Lenz Therapeutics, Inc. have?
Lenz Therapeutics, Inc. has 31,354,395 shares outstanding.
What happened to Lenz Therapeutics, Inc.’s price movement after its last earnings report?
Lenz Therapeutics, Inc. reported an EPS of -$1.02 in its last earnings report, beating expectations of -$1.05. Following the earnings report the stock price went down -3.263%.
Which hedge fund is a major shareholder of Lenz Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LENZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LENZ Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.40 (345.26% Upside)
$24.40 (345.26% Upside)
Blogger Sentiment
Bullish
LENZ Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 50.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.86%
Trailing 12-Months
Company Description
Lenz Therapeutics, Inc.
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
LENZ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of encouraging commercial signals and meaningful operational/financial challenges. Positive indicators include strong early patient persistence in the e‑pharmacy channel (60%+ repeat purchasers and mature cohorts trending to ~5 packs/year), a notable >45% month‑over‑month script lift in July after launching telehealth and national TV, expanding global partnerships and multiple regulatory submissions, and a strong cash balance (~$220M) with an expected high direct product gross margin (~90%). Offsetting these positives are modest product revenue ($1.7M) relative to high operating expenses (Q2 net loss $31.9M; SG&A $39.4M), limited retail channel pickup and visibility, and the caveat that July’s improvement is an early one‑month signal that may not yet represent a durable trend. Management emphasized discipline in capital allocation and a data‑driven reallocation of commercial spend to activities that demonstrably drive durable patient growth.View all LENZ earnings summariesLENZ Stock 12 Month Forecast
Average Price Target
$24.40
▲(345.26% Upside)
Technical Analysis
Ownership Overview
15.24% Insiders
15.87% Mutual Funds
5.10% Other Institutional Investors
54.84% Public Companies and
Individual Investors